CA2269072A1 - Vascular endothelial growth factor (vegf) nucleic acid ligand complexes - Google Patents

Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Info

Publication number
CA2269072A1
CA2269072A1 CA002269072A CA2269072A CA2269072A1 CA 2269072 A1 CA2269072 A1 CA 2269072A1 CA 002269072 A CA002269072 A CA 002269072A CA 2269072 A CA2269072 A CA 2269072A CA 2269072 A1 CA2269072 A1 CA 2269072A1
Authority
CA
Canada
Prior art keywords
nucleic acid
acid ligand
vegf
vegf nucleic
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002269072A
Other languages
French (fr)
Other versions
CA2269072C (en
Inventor
Nebojsa Janjic
Larry Gold
Paul G. Schmidt
Chandra Vargeese
Michael Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Nexstar Pharmaceuticals, Inc.
Nebojsa Janjic
Larry Gold
Paul G. Schmidt
Chandra Vargeese
Michael Willis
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/739,109 priority Critical patent/US5859228A/en
Priority to US08/739,109 priority
Priority to US08/870,930 priority patent/US6168778B1/en
Priority to US08/870,930 priority
Priority to US08/897,351 priority
Priority to US08/897,351 priority patent/US6051698A/en
Priority to PCT/US1997/018944 priority patent/WO1998018480A1/en
Priority claimed from CA002535449A external-priority patent/CA2535449A1/en
Application filed by Nexstar Pharmaceuticals, Inc., Nebojsa Janjic, Larry Gold, Paul G. Schmidt, Chandra Vargeese, Michael Willis, Gilead Sciences, Inc. filed Critical Nexstar Pharmaceuticals, Inc.
Publication of CA2269072A1 publication Critical patent/CA2269072A1/en
Publication of CA2269072C publication Critical patent/CA2269072C/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol

Abstract

This invention discloses a method for preparing a complex comprised of a VEGF
Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF
Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
CA002269072A 1990-06-11 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes Expired - Lifetime CA2269072C (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US08/739,109 US5859228A (en) 1995-05-04 1996-10-25 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/739,109 1996-10-25
US08/870,930 US6168778B1 (en) 1990-06-11 1997-06-06 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US08/870,930 1997-06-06
US08/897,351 1997-07-21
US08/897,351 US6051698A (en) 1997-06-06 1997-07-21 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
PCT/US1997/018944 WO1998018480A1 (en) 1996-10-25 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002535449A CA2535449A1 (en) 1996-10-25 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Publications (2)

Publication Number Publication Date
CA2269072A1 true CA2269072A1 (en) 1998-05-07
CA2269072C CA2269072C (en) 2006-02-14

Family

ID=27419245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002269072A Expired - Lifetime CA2269072C (en) 1990-06-11 1997-10-17 Vascular endothelial growth factor (vegf) nucleic acid ligand complexes

Country Status (16)

Country Link
EP (2) EP0957929B1 (en)
JP (2) JP3626503B2 (en)
KR (1) KR100514929B1 (en)
AT (1) AT318143T (en)
AU (1) AU733674B2 (en)
CA (1) CA2269072C (en)
DE (4) DE69735292D1 (en)
DK (1) DK0957929T3 (en)
ES (1) ES2259188T3 (en)
IL (2) IL129497D0 (en)
LU (1) LU91252I2 (en)
NL (1) NL300234I2 (en)
NZ (1) NZ334859A (en)
PT (1) PT957929E (en)
RU (1) RU2177950C2 (en)
WO (1) WO1998018480A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
AU782620B2 (en) * 1991-06-10 2005-08-11 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
IL147564D0 (en) 1999-07-14 2002-08-14 Alza Corp Neutral lipopolymer and liposomal compositions containing same
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
WO2002026932A2 (en) * 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
ES2346640T4 (en) * 2001-10-26 2011-04-26 Noxxon Pharma Ag Nucleic acid l-modified.
IL161327D0 (en) * 2001-11-09 2004-09-27 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO2004094614A2 (en) 2003-04-21 2004-11-04 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AT516366T (en) 2002-07-25 2011-07-15 Archemix Corp Regulated aptamer-therapeutics
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP3034089A1 (en) 2004-11-02 2016-06-22 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
FR2852606A1 (en) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med In vitro method for simultaneous inhibition of several genes, useful for treating cancer or viral infection, using a ligand that binds to a common site in the genes and induces cutting by topoisomerase
CL2004001996A1 (en) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Anti-VEGF aptamers (vascular endothelial growth factor) with blocking nucleotide 5'-5 'or 3'-3' inverted, composition containing it, useful for disorders neovascularization.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PL2860251T3 (en) 2004-02-12 2019-02-28 Archemix Llc Aptamer therapeutics useful in the treatment of complement-related disorders
EP1737497A2 (en) * 2004-04-13 2007-01-03 (Osi) Eyetech, Inc. Nucleic acid aptamers conjugated to high molecular weight steric groups
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
EP1907590B1 (en) 2005-06-30 2012-09-19 Archemix LLC T7 rna polymerase and methods for the generation of fully 2'-modified nucleic acid transcripts
EP1912676A2 (en) * 2005-07-28 2008-04-23 (Osi) Eyetech, Inc. Cyclitol linker polymer conjugate
US20090324551A1 (en) 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
KR100877824B1 (en) 2005-11-11 2009-01-12 한국생명공학연구원 E2EPF ubiquitin carrier protein-von Hippel-Lindau interaction and uses of thereof
US20100056439A1 (en) * 2005-12-06 2010-03-04 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
JPWO2007080902A1 (en) * 2006-01-11 2009-06-11 協和発酵キリン株式会社 Inhibiting composition expression of a target gene in the eye and of the disease in the eye therapeutics
DK2596807T3 (en) 2006-03-08 2016-03-07 Archemix Llc Complement aptamer AND ANTI-C5 FUNDS FOR USE IN THE TREATMENT OF EYE DISEASES
PT2510946E (en) 2007-02-07 2015-11-23 Univ California Conjugates of synthetic tlr agonists and uses therefor
EP2370581B1 (en) * 2008-12-04 2016-08-03 CuRNA, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
AU2010226434A1 (en) 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
CN102884192A (en) 2009-11-23 2013-01-16 国家健康与医学研究院 Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
TWI510246B (en) 2010-04-30 2015-12-01 Molecular Partners Ag Modified binding proteins inhibiting the vegf-a receptor interaction
EP2618846A1 (en) * 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US20150337308A1 (en) 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
US9958448B2 (en) 2012-10-23 2018-05-01 Caris Life Sciences Switzerland Holdings Gmbh Aptamers and uses thereof
WO2014100434A1 (en) 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
CN105264072A (en) 2013-03-22 2016-01-20 国立大学法人东京大学 Aptamer to il-17 and use thereof
CA2922689A1 (en) 2013-08-28 2015-03-05 Caris Life Sciences Switzerland Holdings Gmbh Oligonucleotide probes and uses thereof
EP3230316A1 (en) 2014-12-11 2017-10-18 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
EP3332812A1 (en) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid-based assembly and use of the assembly in cancer therapy
WO2018229034A1 (en) 2017-06-14 2018-12-20 Bayer Pharma Aktiengesellschaft Non-antibody vegf antagonists for the treatment of neovascular glaucoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462145B1 (en) * 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)

Also Published As

Publication number Publication date
AU4990497A (en) 1998-05-22
NL300234I2 (en) 2006-10-02
EP0957929A1 (en) 1999-11-24
IL129497D0 (en) 2000-02-29
AU733674B2 (en) 2001-05-24
DE69735292T2 (en) 2006-10-19
AT318143T (en) 2006-03-15
DE69735292D1 (en) 2006-04-27
EP1685842A3 (en) 2006-11-29
JP3626503B2 (en) 2005-03-09
IL129497A (en) 2009-06-15
DK0957929T3 (en) 2006-07-03
EP1685842A2 (en) 2006-08-02
WO1998018480A1 (en) 1998-05-07
EP0957929B1 (en) 2006-02-22
LU91252A9 (en)
ES2259188T3 (en) 2006-09-16
JP4160038B2 (en) 2008-10-01
DE122006000029I2 (en) 2007-11-08
JP2001505191A (en) 2001-04-17
PT957929E (en) 2006-06-30
RU2177950C2 (en) 2002-01-10
LU91252I2 (en) 2006-08-14
DE122006000029I1 (en) 2006-10-19
NZ334859A (en) 2001-02-23
KR100514929B1 (en) 2005-09-15
EP0957929A4 (en) 2003-06-25
NL300234I1 (en) 2006-09-01
KR20000052697A (en) 2000-08-25
CA2269072C (en) 2006-02-14
JP2005046160A (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU662102B2 (en) Non-destructive carriers for cyclodextrin complexes
TW577880B (en) Novel carboxylic acid derivatives, their preparation and use
AU769516C (en) Method for obtaining (in vitro) recombined polynucleotide sequences, sequence banks and resulting sequences
AU637847B2 (en) Preparation method for alpha,beta-unsaturated ketones
DE69103104D1 (en) Microspheres which water-soluble materials are released at a predetermined speed, and method for manufacturing the same.
DE68921941D1 (en) Macrocyclic bifunctional chelating agents, complexes thereof and their conjugated antibodies.
EP0831608A3 (en) Programmable radio subscription system for receiving selectively defined information
AU2972892A (en) Metallocenes having benzo-fused indenyl derivatives as ligands, processes for their preparation and their use as catalysts
ZA9708541B (en) Thermal-fuse plug-through, plug-in diffuser.
AU691115B2 (en) Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin
CA2286330A1 (en) Anti-vegf antibodies
PL202058B1 (en) Multiple cytokine−antibody complexes
EP0417572A3 (en) Extended drug delivery of small, water-soluble molecules
ZA200103816B (en) Player information delivery.
CY2355B1 (en) Method for the preparation of monomeric calicheamicin derivative/carrier conjugates.
MXPA02001498A (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
ZA200201118B (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents.
EP0621714A3 (en) Information services platform.
MX202412B (en) Water-soluble copolymers, process for producing the same and their use.
CA2202239A1 (en) Liquid absorbent solutions for separating nitrogen from natural gas
AU4728899A (en) Method for preparing oligonucleotides with boranophosphate linkages
AU2529192A (en) Gaming machine information, communication and display system
EP1014791A4 (en) Method for lowering serum lipid levels employing an mtp inhibitor in combination with another cholesterol lowering drug
CA2305704A1 (en) Peptide/lipid complex formation by co-lyophilization
ZA9711560B (en) Propiophenone derivatives and process for preparing the same.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20171017